Bgm (BGM) Common Equity (2019 - 2025)
Bgm's (BGM) quarterly Common Equity came in at $390.9 million in Q3 2025, up 814.47% year-on-year from $42.7 million in Q3 2024, and up 113.02% on a QoQ basis from $183.5 million in Q1 2025.
Bgm (BGM) Common Equity (2019 - 2025) Analysis & Trends
Bgm (BGM) has 7 years of Common Equity data on file, last reported at $390.9 million in Q3 2025.
- On a quarterly basis, Common Equity rose 814.47% year-over-year to $390.9 million in Q3 2025; TTM through Sep 2025 was $390.9 million, a 814.47% increase from a year earlier, with the FY2025 full-year figure at $390.9 million, up 814.47% from the prior year.
- Common Equity for Q3 2025 stood at $390.9 million, up from $183.5 million in the prior quarter.
- Over the last five years, Common Equity for BGM reached as high as $57507.3 billion in Q1 2022 and fell as low as $42.7 million in Q3 2024.
- Historically, Common Equity has averaged $12471.5 billion across 5 years, with a median of $56.7 million in 2021.
- Across the five-year window, Common Equity slumped 100.0% in 2024 and surged 814.47% in 2025, its largest moves.
- Year by year, Common Equity stood at $56.7 million in 2021, then dropped by 3.01% to $55.0 million in 2022, then fell by 19.31% to $44.4 million in 2023, then retreated by 3.62% to $42.7 million in 2024, then jumped by 814.47% to $390.9 million in 2025.
- Per Business Quant data, the three most recent Common Equity figures were $390.9 million in Q3 2025, $183.5 million in Q1 2025, and $42.7 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 5.90 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 4.27 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Bgm | 33.55 Mn | 23.73 Mn | - | 390.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 390.88 Mn |
| Mar 31, 2025 | 183.49 Mn |
| Sep 30, 2024 | 42.74 Mn |
| Mar 31, 2024 | 44.92 Mn |
| Sep 30, 2023 | 44.35 Mn |
| Mar 31, 2023 | 54,735.30 Bn |
| Sep 30, 2022 | 54.96 Mn |
| Mar 31, 2022 | 57,507.30 Bn |
| Sep 30, 2021 | 56.67 Mn |
| Sep 30, 2020 | 28.84 Mn |
| Sep 30, 2019 | 22.64 Mn |